Schultz A, Saville BR, Marsh JA, Snelling TL. An introduction to clinical trial design. Paediatr Respir Rev. 2019;32:30–35

CAS  PubMed  Google Scholar 

Yang X, Yang C, Zhang S, Geng H, Zhu AX, Bernards R, et al. Precision treatment in advanced hepatocellular carcinoma. Cancer Cell. 2024;42(2):180–197

CAS  PubMed  Google Scholar 

Wang Y, Deng B. Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers. Cancer Metastasis Rev. 2023;42(3):629–652

PubMed  Google Scholar 

Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet (London, England). 2018;391(10126):1163–1173

CAS  PubMed  Google Scholar 

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905

CAS  PubMed  Google Scholar 

Ladd AD, Duarte S, Sahin I, Zarrinpar A. Mechanisms of drug resistance in HCC. Hepatology (Baltimore, MD). 2024;79(4):926–940

PubMed  Google Scholar 

Li J, Bai H, Gao Z, Gao L, Wang W, Li Y, et al. Global, regional, and national temporal trends in incidence and mortality for liver cancer due to hepatitis B, 1990–2021: a decomposition and age-period-cohort analysis for the global burden of disease study 2021. Hepatol Int. 2024. https://doi.org/10.1007/s12072-024-10765-4

Article  PubMed  Google Scholar 

Pinheiro PS, Jones PD, Medina H, Cranford HM, Koru-Sengul T, Bungum T, et al. Incidence of etiology-specific hepatocellular carcinoma: diverging trends and significant heterogeneity by race and ethnicity. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Associat. 2024;22(3):562-571.e568

Google Scholar 

MacKay M, Afshinnekoo E, Rub J, Hassan C, Khunte M, Baskaran N, et al. The therapeutic landscape for cells engineered with chimeric antigen receptors. Nat Biotechnol. 2020;38(2):233–244

CAS  PubMed  Google Scholar 

Zhu W, Fan C, Liu B, Qin J, Fan A, Yang Z, et al. Therapeutic targets for hepatocellular carcinoma identified using proteomics and mendelian randomization. J Gastroenterol Hepatol. 2024. https://doi.org/10.1007/s12072-024-10765-4

Article  PubMed  Google Scholar 

Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet (London, England). 2022;400(10360):1345–1362

CAS  PubMed  Google Scholar 

Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151–172

CAS  PubMed  Google Scholar 

Liu J, Wang P, Shang L, Zhang Z, Tian Y, Chen X, et al. TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors versus TACE plus tyrosine kinase inhibitors for the treatment of patients with hepatocellular carcinoma: a meta-analysis and trial sequential analysis. Hepatol Int. 2024;18(2):595–609

PubMed  Google Scholar 

Yang QK, Chen T, Wang SQ, Zhang XJ, Yao ZX. Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself. Angiogenesis. 2020;23(3):279–298

CAS  PubMed  Google Scholar 

Pan K, Farrukh H, Chittepu V, Xu H, Pan CX, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022;41(1):119

CAS  PubMed  PubMed Central  Google Scholar 

Kilgour MK, Bastin DJ, Lee SH, Ardolino M, McComb S, Visram A. Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy. Front Immunol. 2023;14:1166038

CAS  PubMed  PubMed Central  Google Scholar 

Yang Z, Zheng Y, Wu Z, Wen Y, Wang G, Chen S, et al. Association between pre-diagnostic serum albumin and cancer risk: results from a prospective population-based study. Cancer Med. 2021;10(12):4054–4065

CAS  PubMed  PubMed Central  Google Scholar 

Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(8):525–543

PubMed  PubMed Central  Google Scholar 

Kim YH, Kwak MS, Lee B, Shin JM, Aum S, Park IH, et al. Secretory autophagy machinery and vesicular trafficking are involved in HMGB1 secretion. Autophagy. 2021;17(9):2345–2362

CAS  PubMed  Google Scholar 

Montoya S, Bourcier J, Noviski M, Lu H, Thompson MC, Chirino A, et al. Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127. Science. 2024. https://doi.org/10.1126/science.adi5798

Article  PubMed  PubMed Central  Google Scholar 

Golding B, Luu A, Jones R, Viloria-Petit AM. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC). Mol Cancer. 2018;17(1):52

PubMed  PubMed Central  Google Scholar 

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390

CAS  PubMed  Google Scholar 

Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2017;389(10064):56–66

CAS  PubMed  Google Scholar 

Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54–63

CAS  PubMed  PubMed Central  Google Scholar 

Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282–296

CAS  PubMed  Google Scholar 

Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, et al. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann Oncol. 2024;35(5):448–457

CAS  PubMed  Google Scholar 

Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1480–1492

CAS  PubMed  Google Scholar 

Trevisani F, Brandi G, Garuti F, Barbera MA, Tortora R, Casadei Gardini A, et al. Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. J Cancer Res Clin Oncol. 2018;144(2):403–414

CAS  PubMed  Google Scholar 

Granito A, Marinelli S, Terzi E, Piscaglia F, Renzulli M, Venerandi L, et al. Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure. Digest Liver Dis Offi J Ital Soci Gastroenterol Associat Stud Liver. 2015;47(6):518–522

CAS  Google Scholar 

Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(5):293–313

CAS  PubMed  Google Scholar 

Granito A, Facciorusso A, Sacco R, Bartalena L, Mosconi C, Cea UV, et al. TRANS-TACE: Prognostic role of the transient hypertransaminasemia after conventional chemoembolization for hepatocellular carcinoma. J Pers Med. 2021. https://doi.org/10.3390/jpm11101041

Article  PubMed  PubMed Central  Google Scholar 

Li Y, Wang F, Geng Z, He T, Song Y, Wu J, et al. HBx promotes tumorigenicity through RRM2-mediated autophagy in hepatocellular carcinoma. Cell Biosci. 2024;14(1):116

PubMed  PubMed Central  Google Scholar 

Dauch D, Rudalska R, Cossa G, Nault JC, Kang TW, Wuestefeld T, et al. A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer. Nat Med. 2016;22(7):744–753

CAS  PubMed  Google Scholar 

Siddique HR, Feldman DE, Chen CL, Punj V, Tokumitsu H, Machida K. NUMB phosphorylation destabilizes p53 and promotes self-renewal of tumor-initiating cells by a NANOG-dependent mechanism in liver cancer. Hepatology (Baltimore, MD). 2015;62(5):1466–1479

CAS  PubMed  Google Scholar 

Adhikari B, Bozilovic J, Diebold M, Schwarz JD, Hofstetter J, Schröder M, et al. PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase. Nat Chem Biol. 2020;16(11):1179–1188

CAS